Voting in the ASCO Election is open now until December 2! Meet the candidate for President-Elect, @teekayowo MD, PhD, FASCO. Learn more about Dr. Owonikoko and make your voice heard: bit.ly/4zi4KWm

Proud to support Dr. Taofeek Owonikoko for #ASCO President. As my fearless leader at @UMGCCC , I see daily how he leads: with generosity, vision, fairness and a deep commitment to patients and the people who care for them. ASCO members, please vote! #ASCO @UMmedschool @UMBaltimore @UMGCCC

Help shape the future of @ASCO by voting in the ASCO election. My fellow candidates and I encourage you to visit asco.org/election to learn more about our personal interests in running, then place your vote!

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Nominating Committee. Visit asco.org/election to learn more about the candidates and place your vote!

I am proud to support @DrDawnHershman @columbiacancer for @ASCO Board of Directors. Her research has transformed how we care for patients with breast cancer, and she is Co-Chair of @SWOG. She is the most generous mentor I know and will represent us well. Please vote. Vision and video here - asco.org/about-asco/asco-ove…

HR+ MBC: a crowded, fast-moving trial landscape From Dr. Yeon Hee Park’s excellent presentation at #ESMO26

Addition of Tucatinib to Trastuzumab/Pertuzumab After Local Therapy for Isolated icPD in HER2+mBC: Primary Results of the Ph2 BRIDGET Trial in @ESMO_Open presented at #ESMO2026. Median icPFS not reached (mFUP 19.6 months), 46/47 pts alive @ data cut-off. esmoopen.com/article/S2059-7…

#ESMO26 | BRIDGET A clinically valuable study addressing a real treatment dilemma in HER2+ breast cancer. Adding tucatinib after local therapy for isolated brain progression achieved 18-month intracranial PFS of 59% and extracranial PFS of 98%. Durable CNS control while maintaining an effective systemic regimen—a thoughtful strategy with compelling results. Congratulations to the investigators! @drsarahsam 👏

Tucatinib added to HP is a nice option for 1L low volume brain only disease after local therapy. Particularly in patients with no extracranial disease where the toxicity of ADC is not desired. #ESMO26

Very exciting to have Bridget published simultaneously in @ESMO_Open available open access on line!! @drsarahsam @laura_huppert @PTarantinoMD @OncoAlert

📌 BRIDGET: A phase II trial of tucatinib added to trastuzumab/pertuzumab or ado-trastuzumab emtansine after isolated intracranial progression in patients with advanced HER2-positive breast cancer ✨@drsarahsam #ESMO26 🇪🇸 @OncoAlert #OncoAlertAF

Switching ADC target does not work. Switching payload does. Among 60 TOPO1-ADC-pretreated patients with MBC, using a microtubule (MMAE) ADC led to 30% ORR and DoR of 8.8 mo. #ESMO26 #ESMOAmbassadors

These results are absolutely astounding. This should give us enthusiasm to study more IT targeted therapies. I do need to understand in this trial who got concurrent TDxd as this is likely contributing to results. #ESMO26

First prospective switch trial of Top1 ADC post Top1 ADC in MBC. 0-8% ORR Switching target with same payload simply does not work. Resistance is in payload. Let’s stop talking about “sequencing”. It simply does not work. We need new payloads. #MBC #BCSM #ESMO26

Starting in 2h, Rapid Oral Breast Advanced session, featuring a prospective trial of ADC sequencing (SWITCH), brain mets analysis from DB09, BRIDGET, MRD to predict exceptional response, our CHARISMA translational study, discussions by @LoiSher #PedramRazavi & more! #ESMO26

Anyone interested in cancer medicine needs to see the current front page of @NEJM nejm.org It's one historic advance after another after another on there right now

RT @JaniceTNBCmets: Overall survival matters, but it’s not the ONLY measure of meaningful treatment benefit! For people living with #MBC, d…

Hear ye hear ye!! New pembrolizumab TMB tumor-agnostic threshold is 13 rather than 10. 🔥 Our data suggests it is 16 mut/mb (best threshold) Data coming soon! Responses can be phenomenal. I have patients who went from “next step hospice” to “CR ongoing for years— aka cured”